{"disease":{"id":"chronic-myelogenous-leukemia-cml","name":"chronic myelogenous leukemia cml"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01743989","title":"A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":620,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03959241","title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":431,"lead_sponsor_name":"Medical College of Wisconsin","has_results":true},{"nct_id":"NCT02730299","title":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Gamida Cell ltd","has_results":true},{"nct_id":"NCT06530810","title":"Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT04883125","title":"Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Mansoura University","has_results":false},{"nct_id":"NCT01735955","title":"Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05884333","title":"Cord Blood Transplant in Adults With Blood Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03885830","title":"Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients","phase":"","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"UNC Lineberger Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01517035","title":"Improving Blood Stem Cell Collection and Transplant Procedures","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT01768845","title":"Unrelated Umbilical Cord Blood (UBC)Transplantation","phase":"NA","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"West Virginia University","has_results":true},{"nct_id":"NCT06131801","title":"Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":false},{"nct_id":"NCT02226861","title":"Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT02782403","title":"Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01131325","title":"Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04518644","title":"Nilotinib, for Patients With CML-CP or CML-AP","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}